EFFICACY OF COMPREHENSIVE MEDICAL REHABILITATION IN PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE AND SARCOPENIA: A NARRATIVE REVIEW BASED ON OPEN-ACCESS SOURCES

Authors
  • Manzitova Vazira Furqat qizi

    Assistant, Tashkent State Medical Institute
Keywords:
Metabolic dysfunction-associated steatotic liver disease, MASLD, NAFLD, sarcopenia, comprehensive rehabilitation, resistance exercise, protein, liver fibrosis
Abstract

In patients with metabolic dysfunction-associated steatotic liver disease (MASLD), the loss of skeletal muscle mass and strength (sarcopenia) is associated with disease severity. Evidence on comprehensive rehabilitation that combines physical exercise, dietary correction, and protein provision is scattered. Objective. To assess the effectiveness of comprehensive medical rehabilitation when MASLD and sarcopenia coexist, based on meta-analyses and clinical studies from open sources. Sarcopenia was associated with the risk of NAFLD (OR 1.33–1.58) and the risk of liver fibrosis (OR 1.56–2.03). In a meta-analysis covering 41 studies (n = 185,575), the prevalence of sarcopenia was 23% (95% CI 20–26) in NAFLD and 15% (95% CI 13–17) in the control group. In a network meta-analysis of 28 RCTs (1,606 participants), aerobic and resistance exercise reliably reduced ALT, AST, and GGT compared with control. In sarcopenia, combining exercise with nutrition gave the best results for handgrip strength (MD 3.69; 95% CrI 0.72–5.10), gait speed (MD 0.11), and ASMI (MD 0.35), although the certainty of evidence was low or very low. In patients with MASLD under a 4-week ~30% caloric restriction, a protein intake of ≥0.8 g/kg per day preserved muscle mass. Conclusion. A comprehensive approach that combines exercise (resistance and aerobic), controlled nutrition with adequate protein, and monitoring is justified theoretically and, in part, empirically; however, direct large RCTs in patients with both MASLD and sarcopenia are still lacking.

References

[1] H. A. Musaev and H. D. Xalilov, “Long-term complications of fatty hepatosis [in Uzbek],” Latin American Journal of Education, vol. 5, no. 6, pp. 503–517, 2025. https://doi.org/10.5281/zenodo.17771529

[2] H. A. Musaev and H. D. Xalilov, “Main preconditions for the development of metabolic syndrome [in Uzbek],” Latin American Journal of Education, vol. 5, no. 6, pp. 489–502, 2025. https://doi.org/10.5281/zenodo.17771520

[3] G. I. Fayzillaeva, “Comparative characteristics of morphoelastometric parameters in complicated liver fibrosis [in Uzbek],” Medicine, Pedagogy and Technology: Theory and Practice, vol. 3, no. 11, pp. 147–151, 2025. https://doi.org/10.5281/zenodo.18015562

[4] K. S. Shomurodova and M. N. Kattaboyeva, “Obesity and type 2 diabetes mellitus: metabolic relationship, risk factors, and prevention approaches [in Uzbek],” Synapses: Insights Across the Disciplines, vol. 3, no. 6, pp. 637–646, 2026. https://doi.org/10.5281/zenodo.20837291

[5] U. A. Abdunazarov and A. Babamuratov, “Modern interpretation of liver histology in metabolic dysfunction-associated steatotic liver disease [in Uzbek],” 21st Century: Current Problems in the Development of Innovative Technologies, Science and Education, Republican Scientific and Practical Conference [in Uzbek], vol. 4, no. 4, pp. 52–60, 2026. https://doi.org/10.5281/zenodo.19552602

[6] R. T. Axmadjonov, “Visceral obesity and insulin resistance: pathophysiological basis of the development of metabolic syndrome [in Uzbek],” Zenodo, 2026. https://doi.org/10.5281/zenodo.20533246

[7] C. Cai, X. Song, Y. Chen, X. Chen, and C. Yu, “Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease: A systematic review and meta-analysis,” Hepatol. Int., vol. 14, no. 1, pp. 115–126, 2020. https://doi.org/10.1007/s12072-019-09964-1

[8] S. Giri, P. Anirvan, S. Angadi, A. Singh, and A. Lavekar, “Prevalence and outcome of sarcopenia in non-alcoholic fatty liver disease,” World J. Gastrointest. Pathophysiol., vol. 15, no. 1, pp. 91100, 2024. https://doi.org/10.4291/wjgp.v15.i1.91100

[9] X. Zuo, D. Chen, Y. Kang, X. Hu, et al., “Sarcopenia as a risk factor for nonalcoholic fatty liver disease and liver fibrosis: An updated systematic review and meta-analysis,” Front. Nutr., vol. 13, Art. no. 1726600, 2026. https://doi.org/10.3389/fnut.2026.1726600

[10] H. Hussaini, F. Woreta, O. Sarah, et al., “Association between metabolic dysfunction-associated steatotic liver disease and sarcopenia: A systematic review and meta-analysis,” Cureus, vol. 17, Art. no. e94766, 2025. https://doi.org/10.7759/cureus.94766

[11] A. Singh, A. Buckholz, S. Kumar, and C. Newberry, “Implications of protein and sarcopenia in the prognosis, treatment, and management of metabolic dysfunction-associated steatotic liver disease (MASLD),” Nutrients, vol. 16, no. 5, Art. no. 658, 2024. https://doi.org/10.3390/nu16050658

[12] F. Hong, Y. Liu, V. R. Lebaka, A. Mohammed, W. Ye, B. Chen, and M. Korivi, “Effect of exercise training on serum transaminases in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis,” Front. Physiol., vol. 13, Art. no. 894044, 2022. https://doi.org/10.3389/fphys.2022.894044

[13] M. Huang, J. Yang, Y. Wang, and J. Wu, “Comparative efficacy of different exercise modalities on metabolic profiles and liver functions in non-alcoholic fatty liver disease: A network meta-analysis,” Front. Physiol., vol. 15, Art. no. 1428723, 2024. https://doi.org/10.3389/fphys.2024.1428723

[14] R. Zhao, Y. Dong, Q. Zheng, and J. Yao, “Exercise and nutrition strategies for sarcopenia in older adults: Evidence from a network meta-analysis based on EWGSOP and AWGS criteria,” Front. Nutr., vol. 12, Art. no. 1685014, 2025. https://doi.org/10.3389/fnut.2025.1685014

[15] C. B. Kim, J. Sung, D. Ahn, E. A. Jo, K. W. Baek, H. R. Heo, J. H. Oh, F. Zhang, H. S. Park, H. S. Kim, and J. J. Park, “Independent and combined effects of resistance training and whey protein on skeletal muscle mass and function in individuals with MASLD under caloric restriction,” Nutrients, vol. 18, no. 1, Art. no. 83, 2026. https://doi.org/10.3390/nu18010083

[16] B. M. Vladutu, D. Matei, A. M. Amzolini, C. Kamal, and M. R. Traistaru, “A prospective controlled study on the longitudinal effects of rehabilitation in older women with primary sarcopenia,” Life, vol. 15, no. 4, Art. no. 609, 2025. https://doi.org/10.3390/life15040609

[17] I. Churilov, L. Churilov, K. Brock, D. Murphy, R. J. MacIsaac, and E. I. Ekinci, “The association between sarcopenia and functional improvement in older and younger patients who completed inpatient rehabilitation: A prospective cohort study,” Front. Rehabil. Sci., vol. 2, Art. no. 692896, 2021. https://doi.org/10.3389/fresc.2021.692896

[18] S. Surma and Ł. Bułdak, “Editorial: Metabolic dysfunction-associated steatotic liver disease (MASLD) – pathogenesis, prevention and treatment,” Front. Endocrinol., vol. 16, Art. no. 1703019, 2025. https://doi.org/10.3389/fendo.2025.1703019

[19] I. E. Pleshchev, V. N. Nikolenko, E. E. Achkasov, Y. I. Preobrazhenskiy, L. A. Gridin, A. N. Shkrebko, and M. V. Tsoller, “The effect of exercise and nutritional support on elderly and senile patients with sarcopenic obesity,” Acta Biomed. Sci., vol. 9, no. 3, pp. 14–25, 2024. https://doi.org/10.29413/ABS.2024-9.3.2

[20] I. E. Pleshchev, E. E. Achkasov, V. N. Nikolenko, A. N. Shkrebko, and I. V. Ivanova, “Methods of physical rehabilitation of elderly people for the prevention and treatment of sarcopenia,” Acta Biomed. Sci., vol. 8, no. 2, pp. 80–92, 2023. https://doi.org/10.29413/abs.2023-8.2.8